Last checked at 
FRANKFURT, Feb 10 (Reuters) - Astrazeneca said
global interest in government purchase agreements for its
COVID-19 vaccine was driven by strong demand in Latin America,
the Middle East and Asia, even as aggregate global demand this
year will fall.
Speaking on a media call after the release of the company's
fourth-quarter results, CEO Pascal Soriot said the shot, branded
Vaxzevria, is receiving a "fantastic welcome" in those regions.
The drugmaker earlier flagged a likely fall in
COVID-19-related product sales this year, as an expected decline
in vaccine revenue is to be partially offset by growth in sales
of its antibody drug Evusheld.
(Reporting by Ludwig Burger and Pushkala Aripaka; editing by
Jason Neely)
